Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Biochemical Reagents>Upadacitinib
Upadacitinib
  • Upadacitinib
  • Upadacitinib
  • Upadacitinib
  • Upadacitinib
  • Upadacitinib

Upadacitinib NEW

Price $57 $55 $52
Package 1box 5box 10box
Min. Order: 1box
Supply Ability: 5000 box
Update Time: 2024-04-23

Product Details

Product Name: Upadacitinib CAS No.: 1310726-60-3
Min. Order: 1box Purity: 99%
Supply Ability: 5000 box Release date: 2024/04/23

Article illustration

Upatinib sustained-release tablet is a selective JAK inhibitor developed by AbbVie and approved by the National Drug Administration in February 2022 for refractory, moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older who do not respond well to or are not suitable for other systemic therapies, such as hormonal or biologic agents. The launch of Upatinib sustained-release tablets provides more options for the treatment of atopic dermatitis patients. Approved by the State Drug Administration in March 2022 for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have poor response or intolerance to one or more TNF inhibitors and adult patients with active psoriatic arthritis (PsA) who have poor response or intolerance to one or more DMARDs. Upatinib sustained-release tablets became the first targeted therapy approved in China to treat PsA, opening a new era of targeted therapy for PsA in China. On February 20, 2023, Upatinib sustained release tablets were approved by the State Food and Drug Administration for the treatment of adult patients with moderate to severe active ulcerative colitis who have poor response to one or more TNF inhibitors or are intolerant or conjunctive, becoming the four approved indications in China after atopic dermatitis, psoriatic arthritis and rheumatoid arthritis. It is also the first approved indication of the drug in the field of gastroenterology in China.

It works by blocking the activity of Janus kinase in the JAK-STAT signaling pathway, an intracellular pathway that plays a major role in the release of pro-inflammatory cytokines that stimulate inflammation in rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis


Hebei Weimiao Network Technology Co., Ltd. is a professional production and sales of chemical, cosmetic raw materials, plant extracts, cosmetics, pharmaceutical intermediates, metal materials manufacturers. 


Founded in Hebei Province, the company has developed into a professional enterprise integrating

production, sales and technology development. At present, our products havebeen exported to Europe, the Middle East, Southeast Asia, the United States, Latin America, South America, Australia and other countries and regions. We will be your proud partner in China.


We will be a Chinese partner that make you proud , and we make efforts to provide you with professional and timely service.Look forward to establishing a good faith and friendly relationship with you.


Company Profile Introduction

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/1g
VIP1Y
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
2024-07-24
$1.00/1g
VIP1Y
Apeloa production Co.,Limited
2024-06-11
$30.00/1kg
VIP1Y
hebei hongtan Biotechnology Co., Ltd
2024-05-17
$0.00/25kg
VIP1Y
PUSHAN INDUSTRIAL (SHAANXI) CO.,LTD
2024-05-15
$0.10/1kg
VIP2Y
Zibo Hangyu Biotechnology Development Co., Ltd
2024-02-16
$0.00/1Kg/Bag
VIP4Y
Sinoway Industrial co., ltd.
2023-11-03
$0.00/1g
VIP2Y
shandong perfect biotechnology co.ltd
2023-08-02
$0.00/1kg
VIP2Y
Hangzhou ICH Biofarm Co., Ltd
2023-06-30
$20.00/1kg
Hebei Brisk New Material Technology Co. , Ltd.
2023-06-01
$300.00/1kg
VIP6Y
Anhui Dexinjia Biopharm Co., Ltd
2023-04-02
  • Since: 2015-04-17
  • Address: Building A, Zhonghua Street, Qiaoxi District, Shijiazhuang City, Hebei Province
INQUIRY